| Project/Area Number |
26830112
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Okayama Tetsuya 京都府立医科大学, 医学(系)研究科(研究院), 助教 (30636535)
|
|---|
| Research Collaborator |
Mizushima Katsura
Yasuda Tooyo
Doi Toshifumi
Ishikawa Takeshi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 癌免疫療法 / 細胞療法 / 免疫チェックポイント阻害剤 / 癌免疫治療 / PD-1 / ＮＫ細胞 |
|---|
| Outline of Final Research Achievements |
The main objective of this research is to conduct basic studies on the combination of cellular immunotherapy and suppressive immune checkpoint inhibitor. Since the expansion rate of mouse NK expansion was insufficient, NK cells were separated directly from mouse spleen, and the number of cells was smaller than planned, so we administrated NK cells to local tumor site directly. In addition, we planned to administer the anti-PD-1 antibody drug locally, the concentration was examined, and we decided the optimum concentration was 10 μg / mouse. Based on these conditions, combined study was conducted and the anti-tumor effect was enhanced by combination therapy compared with single treatment of each of anti-PD-1 antibody drug and NK cell therapy, and we will plan to examine detail of this result.
|
